Biotech Pharmaceutical
Lead sent by Charlie Huntingdon; LSF 15 Spin out from Penn OncoViRx is committed to the discovery and development of novel, small molecule inhibitors for the treatment of a range of hematological malignancies. Our mission is to treat hematological cancers with cost-effective, low-side effect, and highly efficient therapies.